Related Experiment Video
Updated: May 28, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Anticholinergic scales and their relation to polypharmacy, cognition, and functional losses in aged in Brazil
Mônica de Souza Brito Conti1, Adriana Sañudo1, Luiz Roberto Ramos1
1Programa de Pós-Graduação em Saúde Coletiva, Departamento de Medicina Preventiva, Universidade Federal de São Paulo. R. Botucatu 740, 4º andar, Vila Clementino. 04223-062 São Paulo SP Brasil. msbconti@unifesp.br.
Abstract:
Aged have a high consumption of medications with anticholinergic activity (MAA), being more vulnerable to adverse events. Using the anticholinergic risk scales, we investigated the prevalence and burden of MAA in the aged, the agreement between the scales and the implications of using MAA with a burden of 2 and 3 on the scales in relation to polypharmacy, cognition and functionality. Cross-sectional study with aged, of both sexes, aged ≥ 60 years old. The prevalence and burden of MAA were investigated by scales: anticholinergic drug scale (ADS), anticholinergic risk scale (ARS), anticholinergic cognitive burden scale (ACB), Brazilian scale of medications with anticholinergic activity (BSMAA). We analyzed the agreement of the scales with Kappa coefficient and investigated by logistic regression the association of MAA with: gender, age, polypharmacy; cognitive capacity (MMSE) and functional capacity (BOMFAQ questionnaire). Of those interviewed, 1,143 aged used medication and 53.5% used MAA. A good agreement was found between: ADS/ACB (0.642), ADS/SBMAA (0.669), ACB/SBMAA (0.656). In the multivariate analysis: gender and polypharmacy were statistically significant.
More Related Videos
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Alzheimer's Disease: Treatment